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As a series of endeavors to establish suitable measures for the sound development of regenerative
medicine using human stem cell-based products, we studied scientiﬁc principles, concepts, and basic
technical elements to ensure the quality and safety of therapeutic products derived from allogeneic
human somatic stem cells, taking into consideration scientiﬁc and technological advances, ethics, reg-
ulatory rationale, and international trends in human stem cell-derived products. This led to the devel-
opment of the Japanese ofﬁcial Notiﬁcation No. 0907-3, “Guideline on Ensuring the Quality and Safety of
Pharmaceuticals and Medical Devices Derived from the Processing of Allogeneic Human Somatic Stem
Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of
Japan, on September 7, 2012. The present paper describes the background information and development
of our study and the resulting guidance. For products derived from allogeneic somatic stem cells, major
points to consider include 1) history, the source, and derivation of starting cells; 2) donor screening/
testing and donor eligibility, especially in relation to the presence of adventitious agents, potential
occurrence of donor-derived diseases, and immunocompatibility; 3) clinical records of a donor; 4)
multipotency and self-replication ability of allogeneic human somatic stem cells; 5) cell banking; 6)
potential presence of viruses in the ﬁnal product; 7) extensive characterization of the cells at critical
stage(s) of manufacture; 8) robustness of the manufacturing process; 9) quality consistency of the
products such as the ﬁnal products and critical intermediate(s) if any; and 10) robust application and
function of the ﬁnal products in a cell environment different fromwhere the original cells were localized
and were performing their natural endogenous function. The ultimate goal of this guidance is to provide
suitable medical opportunities as soon as possible to the patients with severe diseases that are difﬁcult to
treat with conventional modalities.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).s a distinct product from both conventional pharmaceuticals and medical devices according to the revised Pharma-
nd Medical Devices, and Other Therapeutic Products Act. (Akinori Hara, Daisaku Sato, and Yasuyuki Sahara: New
d Therapies in Japan. Therapeutic Innovation & Regulatory Science. 2014; 48(6): 681-688.)
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served as the basis for the ﬁnal draft guidelines. After extensiveThe details of the present study were described in a previous
paper1). The present paper summarizes points that are closely
related to those presented in the earlier paper.
Regenerative medicine using cell-based products that are
derived from the processing of human cells and tissues is keenly
anticipated in Japan because of difﬁculties with securing human
organs and tissues in our country. With technology breakthroughs
and research advances, people are increasingly hopeful that med-
ical technology using novel cell-based products will develop into
new therapies.
In Japan, translational research to regenerative medicine is
advancing rapidly. In particular, considerable work has been done
to develop products that make use of human stem cells, i.e., somatic
stem cells such as mesenchymal stem cells, embryonic stem (ES)
cells, and induced pluripotent stem (iPS) cells. Thus, there is an
urgent need to prepare relevant guidelines on the evaluation of
products expected in the near future. Identifying at an early stage of
development the technical, medical, and ethical conditions neces-
sary for the utilization of various types of stem cells at an early stage
of development is vital for their rapid application to the treatment
of patients.
In the ﬁscal year 2008, the Japanese Ministry of Health, Labour
and Welfare convened a panel of experts: the “Study Group on
Ensuring the Quality and Safety of Pharmaceuticals and Medical
Devices Derived from the Processing of Human Stem Cells.”
The panel was established as a scientiﬁc research project of the
Japanese Ministry of Health, Labour and Welfare and has been
chaired by Dr. Takao Hayakawa since its conception.
The objective of the study group is to promote the sound
development of products derived from human stem cells by
investigating scientiﬁc and technological advances, ethics, the
regulatory rationale, and international trends regarding human-
stem-cell-derived products and to establish and implement
appropriate safety evaluation criteria.
As a result of analyses conducted up to 2009, in accordance with
the Pharmaceutical Affairs Law, and with clinical application of the
products derived from human somatic stem cells, iPS cells, ES cells,
and other relevant cells as the goal, the study group concluded that
the appropriate relevant guidelines should be tailored to speciﬁc
cell sources and phenotypes (human autologous versus human
allogeneic; somatic stem cells vs. iPS cells vs. ES cells vs. other cells)
to facilitate efﬁcient, effective, and rational research and develop-
ment (R&D). Points to be considered include but are not limited to
technical details, the manufacturing process, characterization,
quality control, and stability evaluation, and the data necessary to
guarantee the safety and efﬁcacy of the products.
With this perspective in mind and with the desire for consis-
tency in scientiﬁc principles and concepts, 2 interim reports on
draft guidelines on autologous human somatic stem cell-based
products and autologous human iPS cell-based products were
prepared in 2009 according to Japanese Ministry of Health, Labour
and Welfare Notiﬁcation No. 0208003. Three other interim reports
of draft guidelines on allogeneic human somatic stem cell-based
products, allogeneic human iPS cell-based products, and human
ES cell-based products were also prepared according to Japanese
Ministry of Health, Labour and Welfare Notiﬁcation No. 0912006.
These 5 sets of draft guidelines were thoroughly discussed from a
variety of viewpoints. They were then widely circulated among
interested parties as articles in a relevant scientiﬁc journal to allow
readers to comment (Hayakawa T., et al.: Regenerative Medicine
[Journal of the Japanese Society for Regenerative Medicine], 9,
116e180 [2010], in Japanese). Thereafter, these articles were
updated and published as 8 articles (Journal of the Japanese Societydiscussions with the study group and after public consultation, the
Pharmaceuticals and Food Safety Bureau of the JapaneseMinistry of
Health, Labour and Welfare issued 5 notiﬁcations on September 7,
2012, as described in the previous paper [1].
In the present paper, a continuation of the previous article, we
introduce the basic technological requirements for ensuring the
quality and safety of pharmaceuticals and medical devices derived
from the processing of allogeneic human somatic stem cells. The
ﬁnal products derived from the processing of allogeneic human
somatic stem cells, which are multipotent and retain the ability to
self-replicate, should exhibit cell characteristics different from
those of the starting cells as a result of cell processing and may be
applied and can function at a site (cell environment) different from
where the original cells were localized. These concerns have been
added to Notiﬁcation No. 0912006, which serves as the basis for the
present guideline.
Before interpreting and implementing the present guideline, the
following points should be considered. The ultimate goal is to
provide patients with new therapies that utilize regenerative
medicine. The role of the guideline is to present the scientiﬁc
principles, concepts, ideas, and technical elements that will help to
achieve the speciﬁed goal in the most efﬁcient and effective
manner possible. Because situations, circumstances, and products
will vary, the guideline addresses the points of concern in a
comprehensive manner. Therefore, it is important to identify the
relevant testing parameters and evaluation methods by taking into
consideration the characteristics of the cells in question, the spe-
ciﬁc clinical objective, and themethod of application. Those that are
applicable should be justiﬁed and implemented in an appropriate
and ﬂexible manner.
Several points should be kept in mind with respect to the
development of medicinal products for regenerative medicine and
throughout the implementation of this guideline. The desired
products are expected to show a potential as a novel therapeutic
method as a result of relevant proof of concept (POC). Relevant data
and/or information should establish that there are no critical con-
cerns for product safety that might impede the use of the products
in humans for the ﬁrst time. Thorough observance of the Declara-
tion of Helsinki, including proper informed consent and right of
self-determination on the part of the patient, is indispensable.
It should be emphasized again that the primary goal of our
endeavor is to offer suitable treatment options as soon as possible
to patients with severe diseases that are difﬁcult to treat with
conventional modalities. The present guideline should be useful for
this purpose. Therefore, it is important to interpret and employ the
guideline in a ﬂexible and meaningful way. Stringent observance of
the guideline without taking into account the patients and their
speciﬁc situation (which is like putting the cart before the horse)
should be avoided.
It is evident that progress in the application of regenerative
medicine is desirable for maintaining and improving human health.
The development of innovative and revolutionary medicinal
products and therapeutic techniques should beneﬁt our country as
well as the international community. Regenerative medicine is a
great way tomake a peaceful international contribution that will be
a legacy for mankind. In this context, the role of the government is
to promote clinical research and industrialization; regulations and
guidelines are adopted so that we advance towards this common
goal in a scientiﬁc, rational, efﬁcient, and effectivemanner. All those
involved, like players with a common goal in the same arena,
should continue to make efforts to deliver to patients as soon as
possible the revolutionary cell-based products and therapeutic
techniques.
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(Notiﬁcation No. 0907-3, issued by Pharmaceuticals and Food
Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on
September 7, 2012.)
2. Introduction
1. The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of allogeneic human so-
matic stem cells. These products are hereafter referred to as
allogeneic human somatic stem cell-based products or simply as
the “desired cell products.”
There are many types of allogeneic human somatic stem cell-
based products and methods of their clinical application. In
addition, scientiﬁc progress in this ﬁeld is incessant, while
expertise and knowledge are constantly accumulating. There-
fore, it is not always appropriate to consider the present
guidelines all-inclusive and deﬁnitive. Consequently, when
testing and evaluating each product, it is necessary to adopt a
ﬂexible approach on a case-by-case basis, according to the
rationale that reﬂects the scientiﬁc and technological advances
at that point in time.
2. The main purpose of evaluating the quality and safety of the
desired cell products before conducting investigational clinical
trials (e.g., at the time of “clinical trial consultation”) is to
determinewhether there are any quality and/or safety problems
that would obviously hinder initiation of human clinical trials of
the allogeneic human somatic stem cell-based products in
question, whether certain quality attributes (QA) of the product
are understood sufﬁciently to establish a relationship between
the clinical ﬁndings and the QA, and whether consistency of the
QA can be ensured within a deﬁnite range. Simultaneously, it is
important to eliminate as much as possible any known risk
factors associated with product quality and safety using up-to-
date science and technology and to describe the scientiﬁc
appropriateness of the results of such an action. The remaining
presumed risk factors should be weighed against the risks
associated with not performing the trials on patients who suffer
from diseases that are serious and life-threatening, or that
involve marked functional impairment or a marked decrease in
quality of life (QOL) resulting from the loss of a certain degree of
a physical function or form, or for which existing therapies have
limitations and do not result in a cure. Furthermore, it is
important to entrust the patient with the right to make a deci-
sion after receiving all of the available information. When
applying for approval of investigational clinical trials, applicants
can submit a provisional nonclinical data package, which is
prepared rationally by taking into account product aspects and
patient aspects including a balance between the risk of the
product vs. the risk facing the patient with/without treatment in
question, in order to decide to initiate investigational clinical
trials, on the premise that the data package submitted at the
time of marketing application/registration to ensure quality and
safety will be enriched and developed in linewith the guidelines
as the clinical trial progresses.
Finally, applicants are encouraged to discuss with the Pharma-
ceuticals and Medical Devices Agency (PMDA) the type and
extent of data that may be needed to initiate an individual
clinical trial. Because of differences in product origin, target
disease, target patients, application sites, application methods,
and processing methods, there may be numerous variationsamong individual data packages; these differences cannot be
deﬁnitively clariﬁed in the present guidelines.
3. The items, test methods, criteria, and any other technical re-
quirements described in the present guidelines are intended to
be considered, selected, applied, and evaluated to serve each
intended purpose; they do not necessarily require the most
stringent level of interpretation and practice. Applicants are
encouraged to explain and provide justiﬁcation for any consid-
erations regarding the background, selection, application, and
the content as well as the extent of evaluation that are appro-
priate for their own purpose and are scientiﬁcally valid.3. Chapter I. General principles
3.1. Objective
The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of human allogeneic somatic
stem cells (excluding autologous somatic stem cells). These prod-
ucts are hereafter referred to as allogeneic human somatic stem
cell-based products or simply as the “desired cell products.”
3.2. Deﬁnitions
The deﬁnitions of the technical terms used in this guideline are
as follows:
1. “Human somatic stem cells”: Cells that are collected from
humans or cells that are derived from such cells through cell
division and that possess multipotency and maintain the ability
to self-renew or a similar ability. In other words, tissue stem
cells (e.g., hematopoietic stem cells, neural stem cells, mesen-
chymal stem cells [including bone marrow stromal stem cells
and adipose-tissue-derived stem cells], corneal stem cells, skin
stem cells, hair follicle stem cells, intestinal stem cells, hepatic
stem cells, and skeletal muscle stem cells) or cell groups that
have abundant populations of these cells (e.g., whole-bone-
marrow cells that include hematopoietic stem cells), including
vascular precursor cells, umbilical cord blood, and bone marrow
stromal cells. “Human somatic stem cells” also include cells
obtained by culturing these cells in vitro. Human embryonic
stem (ES) cells, human induced pluripotent stem (iPS) cells,
human induced pluripotent stem-like (iPS-like) cells, human
embryonic germ (EG) cells, human multipotent germline stem
(mGS) cells, human parthenogenesis stem cells, human nuclear
transplant stem cells, human cancer cells, human cancer stem
cells, and cells derived from these cells are not included. (Note:
The deﬁnitions of human ES cells, human iPS cells, and human
iPS-like cells are provided in other guidelines, particularly, in
“Guidelines on Ensuring the Quality and Safety of Pharmaceu-
ticals and Medical Devices Derived from the Processing of Hu-
man ES Cells” and “Guidelines on Ensuring the Quality and
Safety of Pharmaceuticals andMedical Devices Derived from the
Processing of Allogeneic/Autologous Human iPS(-like) Cells,”
respectively.)
2. “Processing of cells and tissues”: Any processing of a cell type or
tissue, such as propagation and/or differentiation, production of
a cell line, activation of a cell by pharmaceutical or chemical
treatment, alteration of a biological characteristic, combination
with a noncellular component, and manipulation using genetic
engineering, with the aim of preparing desired cell products to
treat a patient or repair or regenerate tissue.
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cells, isolation of a speciﬁc cell, treatment with antibiotics,
washing, sterilization by g-irradiation or other methods,
freezing, thawing, and other such procedures that are regarded
as minimal manipulations are not considered “processing.”
3. “Manufacture”: Actions undertaken before the ﬁnal product (an
allogeneic human somatic stem cell-based product) is released
to themarket. This includes, in addition to the processing of cells
and tissues, minimal manipulations such as separation of a tis-
sue, homogenization of a tissue, separation of cells, isolation of a
speciﬁc cell, treatment with antibiotics, washing, sterilization by
g-irradiation or other methods, freezing, thawing, and other
procedures that do not change the original properties of the
cells or tissues.
4. “Phenotype”: A morphological or physiological characteristic
that is produced by a certain gene under constant environ-
mental conditions.
5. “HLA typing”: Identiﬁcation of the type of HLA (human leuko-
cyte antigen), a human primary histocompatibility antigen.
6. “Donor”: A person who donates his/her own cells or tissue,
which serve as a raw material for an allogeneic human somatic
stem cell-based product.
7. “Transgenic construct”: A construct that contains a vector for
introducing a target gene (a speciﬁc gene encoding a desired
protein or RNA) into a target cell, the target gene itself, and the
coding sequences of the elements essential for the expression of
the target gene.
4. Chapter II. Manufacturing methods
Describe all important and relevant information concerning the
manufacturing method, taking into account the items listed below.
This information will help to ensure the quality, safety, and efﬁcacy
of the ﬁnal products, and it is important for guaranteeing consis-
tency in quality from the manufacturing perspective. It should be
noted that quality, safety, and consistency are ensured by mutual
complementary measures throughout the manufacturing process.
It is very important that the measures be rational and that they
serve the intended purpose. It is acceptable to omit portion of the
items listed below, if the quality, safety, and constancy of the ﬁnal
products can be established by suitably chosen quality tests, control
of the ﬁnal or intermediate products, or control of the
manufacturing process.
4.1. Raw materials and materials used in manufacturing
4.1.1. Human cells and tissues used as raw materials
4.1.1.1. Source and origin and justiﬁcation of their selection.
Explain the source and origin of the cells and/or tissues used as raw
materials and provide the reasons for selecting these cells and/or
tissues.
4.1.1.2. Characteristics and eligibility of cells and/or tissues used as
raw materials
4.1.1.2.1. Features of biological structure and function, selection
criteria. Provide and explain the reasons for selecting the cells and/
or tissues used as raw materials with reference to characteristics of
their biological structure and function, such as morphological
characteristics, growth characteristics, biochemical indicators,
immunological indicators, speciﬁc substances produced, results of
HLA typing, and other suitably chosen and appropriate genotype or
phenotype indicators (or markers). In particular, demonstrate that
the somatic stem cells used as a raw material possess clinically
useful stemness. Stemness in this case does not necessarily indicate
the potential for multilineage differentiation but refers to theability to differentiate into cells that have expected functions
in vivo. In addition, although demonstrating differentiation in vitro
is desirable, it may sufﬁce to show differentiation in vivo if a
rational explanation is provided. For example, when using
myocardial stem cells, which are somatic stem cells, as a raw ma-
terial, it is acceptable to show that myocardial stem cells can
differentiate into cardiomyocytes. This should lead to the identiﬁ-
cation of the critical cell characteristics that will be employed when
preparing the somatic stem cells as raw materials.
It is recognized that quantitative technological limits on sample
analysis will affect the extent to which such studies can be
performed.
4.1.1.2.2. Donor selection criteria and eligibility. Indicate that the
donor was selected in an appropriate and ethical manner and that
the proper procedure was followed. Establish selection criteria and
eligibility criteria that take into consideration age, sex, ethnic
characteristics, genetic characteristics, the medical history, the
health condition, test parameters related to any type of infection
that may occur because of cell and/or tissue samples, immuno-
logical compatibility, and other characteristics and provide the
justiﬁcation. If donor genomic or gene analysis is undertaken, it
shall be performed in accordance with “Ethical Guidelines for
Analytical Research on Human Genome/Gene,” issued jointly on
February 8, 2013, and revised on November 25, 2014, by the Japa-
nese Ministry of Education, Culture, Sports, Science and Technol-
ogy; Ministry of Health, Labour and Welfare; and Ministry of
Economy, Trade and Industry.
Infection with hepatitis B virus (HBV), hepatitis C virus (HCV),
human immunodeﬁciency virus (HIV), adult human T-lympho-
tropic virus (HTLV), or parvovirus B19 shall be ruled out via
physician-donor interviews and clinical laboratory tests, such as
serological tests and nucleic-acid ampliﬁcation tests. Infectionwith
cytomegalovirus, Epstein-Barr (EB) virus, or West Nile virus shall
also be ruled out, if necessary, via appropriate clinical laboratory
tests.
In addition, further assess and determine the eligibility of do-
nors by examining the medical history (mentioned below) of the
donor, for example, through physician-donor interviews, and
determine whether he/she ever received a blood transfusion or
underwent a transplant procedure.
 Bacterial infections, such as syphilis (Treponema pallidum),
chlamydia, gonorrhea, and tubercle bacillus
 Sepsis or suspected sepsis
 A malignant neoplasm
 Serious metabolic or endocrine disease
 Collagen and blood diseases
 Hepatic diseases
 Conﬁrmed or suspected transmissible spongiform encephalop-
athy (TSE) or other brain disorders
 A speciﬁc genetic disease or a family history of a speciﬁc genetic
disease4.1.1.3. Records related to the donor. Retain complete records
related to the donor so that any information necessary to ensure
the safety of cells and tissues that are used as raw materials can be
veriﬁed. Concrete measures shall be described. For patients and
donors of test samples, it is sufﬁcient to prepare and retain only
speciﬁc information that is related to the intended use of the cells.4.1.1.4. Collection, storage, and transport of cells and tissues
4.1.1.4.1. Eligibility of personnel and medical institutions collecting
the samples. Describe the technical requirements for personnel and
medical institutions that collect the cells and tissues.
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Describe the rationale for selecting the cell and tissue sampling
sites and the sampling method. State why the selected sites are
scientiﬁcally and ethically appropriate. For cell and tissue sampling
methods, indicate the suitability of the equipment and drugs used
and the measures adopted to prevent microbial contamination,
erroneous sampling (mix-up), and cross-contamination.
4.1.1.4.3. Informed consent of donors. Describe the details of the
informed consent, including the clinical application, provided by
the donor of the cells or tissue.
4.1.1.4.4. Protection of donor privacy. Indicate the measures
adopted to ensure the protection of the donors' privacy.
4.1.1.4.5. Tests to ensure donor safety. If tests such as those to
conﬁrm the state of the sampling site need to be performed in order
to ensure the safety of the donor at the time of cell or tissue sam-
pling, describe the details of the tests as well as any interventions
undertaken when the test results indicate that a problem exists.
4.1.1.4.6. A storage method and measures to prevent erroneous
sampling (mix-up). If the cells and/or tissues need to be stored for a
deﬁnite period of time, set the storage conditions and storage
period and provide the justiﬁcation. Describe in detail themeasures
to be taken to prevent erroneous sampling (mix-up).
4.1.1.4.7. Transportation methods. If cells and/or tissues need to
be transported, specify the containers used for transport and the
transportation procedure (including temperature control) and
provide justiﬁcation for their suitability.
4.1.1.4.8. Preparation of records and record-keeping procedures.
Prepare written records for items (4.1.1.4.1) through (4.1.1.4.7)
above and describe the record-keeping procedures in detail.4.1.2. Raw materials other than the target cells and tissues,
materials used in manufacturing
Describe raw materials other than the target cells and tissues as
well as other materials used in the manufacturing process; indicate
their appropriateness for the intended use; and, if necessary,
establish their speciﬁcations (a set of acceptance criteria and
analytical procedures). Proper quality control of these materials
should be implemented.
When so-called Biological Products, or Speciﬁc Biological
Products (refer to Articles 2.9 and 2.10 of the Pharmaceutical Affairs
Law) are used as raw materials, use the minimum amount required
and strictly conform to the relevant laws and regulations, such as
“Standards for Biological Raw Materials” (Notiﬁcation No. 210,
Japanese Ministry of Health, Labour and Welfare, 2003; a partially
revised versionwas issued on September 26, 2014). It is particularly
important to adequately evaluate information related to the inac-
tivation and elimination of viruses and to specify measures for
encouraging retrospective and other studies.4.1.2.1. When culturing cells
(i) Indicate the appropriateness of all media components
including such as additives (e.g., serum, growth factors, and
antibiotics), and reagents, used in the treatment of cells and
set speciﬁcations if necessary. Give consideration to the route
of clinical application and other parameters of the ﬁnal
product when setting speciﬁcations concerning the appro-
priateness of each component.
(ii) Take into consideration the following points with respect to
media components:
(a) The ingredients and water used in media should be of
high quality and high biological purity, and their quality
should be controlled using standards equivalent to thoseused with pharmaceuticals and pharmaceutical
ingredients.
(b) Provide information on all ingredients used in the media
as well as the rationale for their selection, and, if neces-
sary, the quality control and other procedures. However,
widely known and commercially available media prod-
ucts such as DMEM, MCDB, HAM, and RPMI are regarded
as a single raw-material set.
(c) Conduct sterility tests and performance tests on media
that contain all components in order to determine
whether they are suitable as target media. Set speciﬁ-
cations for any other relevant parameters expected to be
controlled in the process and perform proper quality
control.(iii) Heterologous serum or components derived from heterolo-
gous or homologous serum shall not be used unless they are
essential for processes such as cell activation or cell growth.
In particular, for products that may be used repeatedly,
investigate, to the extent possible, ways to avoid using these
serum components. If the use of serum or other such mate-
rials is unavoidable, consider the following points and
investigate ways to prevent the contamination and the
transmission of bacteria, fungi, viruses, and prions from
serum and other related materials as well as treatment
methods for their elimination, to the extent possible, from
the ﬁnal product.
(a) Clarify the origin of the serum or other components.
(b) Make strenuous efforts to minimize the risk of prion
infection, e.g., by strictly avoiding the use of serum from
areas or regions with known outbreaks of bovine spon-
giform encephalopathy (BSE).
(c) Use these batches of serum only after conﬁrming that
they are not contaminated with viruses or other patho-
gens by conducting appropriate tests to prove the
absence of speciﬁc viruses and mycoplasma that origi-
nate in animal species.
(d) Perform appropriate procedures to inactivate and elim-
inate bacteria, fungi, and viruses to an extent that does
not affect activation and growth of the cells. For example,
to avoid the risks associated with latent viral contami-
nation, perform combinations of heat treatment, ﬁltra-
tion, g-irradiation, and/or ultraviolet light treatment, if
needed.
(e) Preserve and store a portion of the serum used in order to
monitor cultured cells for viral infections, to monitor
onset of viral diseases among the patients, and measure
antigen production in response to a component of the
heterologous serum used.(iv) When using feeder cells, conduct quality evaluation while
referring to “Derivation and Characterization of Cell Sub-
strates Used for the Production of Biotechnological/Biological
Products” (Pharmaceutical Notiﬁcation No. 873, issued July
14, 2000, Evaluation and Licensing Division, Pharmaceutical
and Food Safety Bureau, Japanese Ministry of Health, Labour
and Welfare), “Guidelines on Public Health Infection Issues
Accompanying Xenotransplantations” (Notiﬁcation No.
0709001, issued July 9, 2002, Research and Development
Division, Health Policy Bureau, Japanese Ministry of Health,
Labour and Welfare), and “Guidelines on Epithelial Regen-
erative Therapy Using 3T3J2 Strain or 3T3NIH Strain Cells as
Feeder Cells” based on “Guidelines on Public Health Infection
Issues Accompanying Xenotransplantations” (Notiﬁcation
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Division, Health Policy Bureau, Japanese Ministry of Health,
Labour and Welfare) in order to prevent contamination of
feeder cells and the transmission of bacteria, fungi, viruses,
and prions. Indicate methods for the inactivation of cell di-
vision potential and conditions such as cell density when
using the feeder cells. However, if, for example, the feeder
cells or equivalent cells are being used in the manufacture of
a cell or tissue product that has already been used clinically
and whose characteristics and microbiological safety have
already been assessed and conﬁrmed, it is possible to omit
the virus tests or parts of other tests by demonstrating the
appropriateness of these cells.
(v) Avoid the use of antibiotics as much as possible. However, if
the use of antibiotics at the initial stages of processing is
deemed indispensable, attempt to decrease their use at
subsequent steps as much as possible, and clearly indicate
the appropriateness of their use from perspectives such as
the scientiﬁc rationale, estimated residual amounts in the
ﬁnal product, and the effects on the patient. If it has been
determined that an antibiotic can be adequately eliminated,
its use does not need to be restricted. On the other hand, if a
patient has a history of allergy to the antibiotic used, in
principle, this therapeutic method should not be used. If
there is no way to avoid the use of antibiotics, administer
them very carefully and obtain informed consent from the
patient.
(vi) If growth factors are used, show the appropriate quality
control methods using relevant parameters, such as purity
and potency, for which established acceptance criteria and
assay methods are employed, in order to guarantee the
reproducibility of the cell culture characteristics.
(vii) For media components and other components that are used
in processing and that may contaminate the ﬁnal product,
choose components that do not have any harmful biological
effects.4.1.2.2. When combining cells with noncellular components
4.1.2.2.1. Quality and safety of noncellular raw materials. If the
ﬁnal product consists of cells and noncellular components such as a
matrix, medical materials, scaffolds, support membranes, ﬁbers,
and beads, clearly describe in detail the quality and safety of the
noncellular components.
Provide any relevant information concerning the noncellular
raw materials, taking into consideration their type and character-
istics, the form and function in the ﬁnal product, and evaluation of
the quality, safety, and efﬁcacy from the standpoint of the pre-
sumed clinical indication. If using materials that are absorbed by
the body, perform the necessary tests on the degradation products
to address safety concerns.
With respect to the tests that should be carried out, refer to
“Basic Views on Biological Tests Necessary for Regulatory Approval
for Manufactured or Imported Medical Devices” (Notiﬁcation No.
0213001, issued February 13, 2003, Evaluation and Licensing Divi-
sion, Pharmaceutical and Food Safety Bureau, Japanese Ministry of
Health, Labour and Welfare), describe the test results, and provide
justiﬁcation for the use of such raw materials. Use of information
from scientiﬁc literature is encouraged.
4.1.2.2.2. Interactions with target cells. Demonstrate the validity
of the tests used and provide justiﬁcation for the results obtainedfor the following 3 items with respect to the interactions between
noncellular components and cells in the ﬁnal product and in any
intermediate products.
(a) The noncellular components do not have any deleterious
effects on the function, growth capacity, activity, or stability
of the cells in the ﬁnal product required for the presumed
clinical indication or the cells in any intermediate products.
(b) Evaluate to the extent possible any potential interactions
between the cells and noncellular components, taking into
consideration, for example, the mutation, transformation,
and/or dedifferentiation of the cells in the ﬁnal product or
cells in intermediate products.
(c) Show that there is no loss of the expected properties of the
noncellular components for the presumed clinical indication
as a result of any interactions between the noncellular
components and the cells in the ﬁnal and intermediate
products.
4.1.2.2.3. When using noncellular components to isolate the
desired cell products from the application site. When using noncel-
lular components with the objective of segregating the cells from
the application site, conﬁrm their usefulness and safety by referring
to items (a) through (e) below.
(a) When immunological segregation is the objective, describe
its level.
(b) Membrane permeability kinetics and the pharmacological
effects of target physiologically active substances derived
from the cells in the ﬁnal product.
(c) Diffusion of nutritional components and excretory products.
(d) Effects of noncellular components on the area near the
application site.
(e) When a pharmacological effect of a target physiologically
active substance derived from a desired cell product is
anticipated and the objective is segregation of the applica-
tion site and the desired cell product or undifferentiated
cells, conﬁrm that the cells do not leak out, which might
result, for instance, from the degradation of noncellular
components.
4.1.2.3. When cells are subjected to genetic modiﬁcations.
When genes are introduced into cells, provide the following details:
(i) For the target gene (the speciﬁc gene encoding a desired
protein or RNA), information related to its structure and
origin, the method by which it was obtained, cloning
methods, and methods of cell bank preparation, control,
renewal, and other relevant information.
(ii) Nature of the transgene.
(iii) Structure, biological activity, and properties of the desired
protein or RNA derived from the target gene.
(iv) All raw materials, their properties, and procedures (trans-
genic method, origin, and properties of the vector, and
method for obtaining the vector used for introduction of the
transgene) needed to produce the transgenic construct.
(v) Structure and characteristics of the transgenic construct.
(vi) Control and preparation methods for cell and virus banks
that are used to prepare vectors and transgenic constructs.
For manufacturing methods for transgenic cells, refer to Chapter
2 and other sections of “Guidelines for Ensuring the Quality and
Safety of Gene Therapy Pharmaceuticals,” which is an appendix in
“Concerning Guidelines for Ensuring the Quality and Safety of Gene
Therapy Pharmaceuticals” (hereafter referred to as “Gene Therapy
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Pharmaceutical Affairs Bureau, Japanese Ministry of Health and
Welfare on November 15, 1995. In addition, state the appropriate-
ness of the establishment of a cell line in accordance with the ap-
pendix of the same notiﬁcation.
On the basis of the law (Law No. 97, 2003) implemented to
ensure biodiversity by regulating the use (and other aspects) of
genetic recombination-derived organisms, a separate application
procedure for evaluation will be required when living organisms,
including certain cells, “viruses,” and “viroids,” are genetically
modiﬁed. The following cells are not regarded as living organisms:
“human cells” or “cells that have the ability to differentiate or
differentiated cells that are not viable when alone under natural
conditions.”
Regardless of the guidelines mentioned above, if a gene intro-
duced into cells is used as a reagent in the manufacturing process
and does not contribute either chemically or functionally to the
ﬁnal product, it is acceptable to describe, on the basis of current
knowledge, how the quality and safety of the gene conform to the
intended use.
4.2. Manufacturing process
When manufacturing allogeneic human somatic stem cell-
based products, describe in detail the manufacturing method and
verify, to the extent possible, the appropriateness of the method,
using the items listed below, in order to maintain consistency in the
quality of the product.
4.2.1. Lot control
Indicate whether a lot control procedure is applied for ﬁnal
products and intermediate products. If any lot control procedure is
adopted, establish standardized procedures for the makeup and
control of the lot, which may include the lot size, labeling/
numbering, testing method and acceptance criteria.
4.2.2. Manufacturing method
Provide an outline of the manufacturing method, from the
receipt of the cells and tissues to the isolation of somatic stem cells
and the establishment of the ﬁnal product. Describe the technical
details of the process and necessary process control and product
quality control.
4.2.2.1. Tests upon receipt. Establish a battery of tests as well as
acceptance criteria for assessing the suitability of the cells and
tissues that will serve as the raw materials, taking into account the
nature of the cells and their intended use. These may include, for
example, visual tests, microscopic examination, recovery factors of
target cells, cell viability assays, characterization of cells and tis-
sues, and microbiological tests. At the stage of initiating clinical
trials, provide the actual measured values obtained up until that
point with test samples, and propose a provisional set of acceptance
criteria based on these values.
4.2.2.2. Inactivation and elimination of bacteria, fungi, viruses, and
other microorganisms. In cells and tissues that serve as raw mate-
rials, inactivate bacteria, fungi, viruses, and other microorganisms,
if necessary and whenever possible, to the extent possible, without
altering the cellular characteristics (e.g., cell viability, phenotype,
genetic traits, and speciﬁc functions) and quality of the cells and
tissues serving as raw materials. State the suitability of the mea-
sures, procedures, and evaluation methods used if any.
4.2.2.3. Tissue homogenization, cell separation, isolation of speciﬁc
cells, and other techniques. Describe the methods forhomogenization of tissues, separation of cells, and isolation of so-
matic stem cells as well as methods for washing of the cells and
tissues (and other methods), that are performed at the early stages
of manufacturing of somatic stem cell-based products from
collected cells and tissues. When isolating somatic stem cells,
establish methods of cell identiﬁcation.
4.2.2.4. Preparation of cells that are a principal component and active
ingredient in the ﬁnal product. Describe the methods used to collect
human cells and tissues, to isolate somatic stem cells, and to obtain
the cells that serve as the active ingredient in the ﬁnal product. The
items to be described include induction of differentiation, isolation,
and culture of the desired cells, and preparation of the media,
culture conditions, the culture period, and the yield of the cells at
each step. Describe the appropriateness of each method.
4.2.2.5. Establishment and use of cell lines. Establish cell lines after
having determined to the extent possible the genetic background of
the donor. Describe the method of establishment of a cell line and
its appropriateness to the extent possible.
To ensure that the quality of the established cell line remains
stable and consistent, identify the critical quality attributes of the
cells (e.g., cell population purity, morphological features, pheno-
typic markers, karyotype, cell growth properties, and differentia-
tion potency) and set acceptance criteria for them. In addition,
demonstrate the number of passages or cell division within which
the cells remain stable in terms of the criteria speciﬁed.
Discuss the possibility of tumorigenicity and malignant trans-
formation, using an appropriate animal model, where necessary
and appropriate.
4.2.2.6. Establishment of cell banks. When a cell bank is established
at any stage during the manufacture of allogeneic human somatic
stem cell-based products, describe the rationale for preparing the
cell banks; the methods used to prepare the cell banks; the char-
acteristics of the cell banks, and the storage, maintenance, control,
and renewal methods as well as any other processes and tests
performed. Provide justiﬁcation for each. Refer to “Derivation and
Characterisation of Cell Substrates Used for the Production of
Biotechnological/Biological Products” (Pharmaceutical Notiﬁcation
No. 873, issued July 14, 2000, Evaluation and Licensing Division,
Pharmaceutical and Food Safety Bureau, Japanese Ministry of
Health, Labour and Welfare) and other documents.
4.2.2.7. Measures to prevent erroneous sampling (mix-up) and cross-
contamination during the manufacturing process. It is extremely
important to prevent erroneous sampling and cross-contamination
during the manufacturing process when manufacturing the allo-
geneic human somatic stem cell-based products. Therefore,
describe preventive measures for the process.
4.2.3. Characterization of cells that are a principal component and
active ingredient in a ﬁnal product
For such cells, analyze the attributes, such as cell population
purity (to control contamination by nontarget cells), cell viability,
morphological characteristics, cell growth characteristics,
biochemical markers, immunological markers, distinctive sub-
stances produced by the cells, karyotype, and other appropriate
genotypic and phenotypic markers. In addition, characterize their
biological functions if necessary. Furthermore, to evaluate the
appropriateness of the culture duration and the stability of the
cells, use appropriate markers of cell characteristics to demonstrate
that there have been no unintended changes in cells cultured
longer than the proposed culture period. It is acceptable to perform
these studies preliminarily, using test samples obtained from
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clinical trial. On the basis of these test results, identify the critical
cell characteristics that should be used when applying the product
to a patient. Although comprehensive cell characterization is al-
ways desirable, it is not always possible to characterize the cells
fully because there are quantitative limits on sample analysis. Thus,
it is acceptable to perform a limited study to the extent possible.
When cell processing, such as growth within the body, is antici-
pated after a clinical application, clearly demonstrate the functions
expected by describing the speciﬁed criteria with respect to the
passage number or number of cell divisions.
4.2.4. The form and packaging of the ﬁnal products
The form and packaging of the ﬁnal product shall ensure the
quality of the ﬁnal product.
4.2.5. Storage and transport of the ﬁnal product
If an intermediate or ﬁnal products need to be stored and
transported, the storage procedure and duration, the containers
used for transport, and the transportation procedure (including
temperature control) shall be stated and their suitability clearly
indicated (refer to Chapter III).
4.2.6. Consistency of the manufacturing procedure
To assess the consistency of the manufacturing process using
each product (or each lot, if any) obtained from different produc-
tion runs, determine whether they differ signiﬁcantly with respect
to the number of cells, cell viability, and cell characteristics (such as
relevant markers of a phenotype and genotype, functional charac-
teristics, and the percentage of the desired cells) and from the point
of viewof the clinical applicationmethods and the intended clinical
use of the product. It is acceptable to use test samples obtained
from donors in place of the real product that will be prepared for a
clinical trial. Evaluation of intermediate products may provide
insight into the suitability of cells and tissues for use as raw ma-
terials and the validity of the manufacturing process up until the
intermediate-product stage and can provide an appropriate
guidepost en route to the ﬁnal product. Therefore, it may be
reasonable to adopt such an approach, where necessary and
appropriate.
When the manufacturing process involves long cryopreserva-
tion periods or cell cultivation periods, perform sterilization tests at
constant intervals to conﬁrm that sterility has been maintained.
4.2.7. Changes in the manufacturing process
If the manufacturing process is altered at some point during
development and the test results that are obtained using products
manufactured before the change in the manufacturing method are
to be used in the application for clinical trial or regulatory approval,
demonstrate that the products manufactured before and after the
change to the manufacturing process are comparable.
4.3. Quality control of the ﬁnal product
4.3.1. Introduction
The overall quality control strategy for products manufactured
using human somatic stem cells include speciﬁcations (a set of
acceptance criteria and analytical procedures) for the ﬁnal prod-
ucts, quality control of raw materials for each therapeutic applica-
tion to patients, veriﬁcation of the suitability of the manufacturing
process, maintenance of consistency, and proper quality control of
any intermediate products.
Speciﬁcations will differ among ﬁnal products, depending on
the type and properties of the desired cells and tissues,
manufacturing methods, intended clinical use, methods of clinicalapplication, stability, and test methods. These differences shall be
taken into consideration when setting the acceptance criteria and
test procedures. In addition, speciﬁcations shall be set and justiﬁed
from the standpoint of achieving the purpose of quality control as a
whole, by taking into consideration the mutually complementary
relationships among 1) veriﬁcation of the suitability of the
manufacturing process, 2) the method for maintaining consistency,
and 3) quality control of the raw materials and intermediate
products. The purpose of the assessment at the initiation of clinical
trials is to conﬁrm that the product is unlikely to pose signiﬁcant
quality/safety problems for use in investigational clinical trials.
Therefore, it is possible to set provisional speciﬁcations with
allowance for some variation on the basis of the measured values
obtained for a few test specimens, as long as one can explain about
the relationship between the results of clinical tests and the quality
attributes after the clinical trial. However, testing for sterility and
the absence of mycoplasma is essential. It should be noted that the
quality control strategy, including speciﬁcations, should be
enriched and developed as the clinical trial progresses.
4.3.2. Quality control of the ﬁnal product
Refer to the general quality control parameters and tests shown
below, set necessary and appropriate speciﬁcations for the ﬁnal
product, and provide the rationale for the speciﬁcations set.
Set appropriate acceptance criteria and test procedures for in-
dividual products that do notmake up a lot and for products that do
make up a lot because normally each lot is the unit subject to
quality control.
4.3.2.1. Cell number and cell viability. For cells that are an active
ingredient in the ﬁnal product, determine the cell number and
viability in the ﬁnal product or, if needed, in an appropriate inter-
mediate product. At the beginning of the clinical trial, it is accept-
able to set provisional acceptance criteria that are based on
measured values obtained for a small number of test samples.
4.3.2.2. Tests of identity. Conﬁrm that the cells are the intended
target cells by assessing important cell characteristic(s), such as
morphological characteristics, biochemical markers, immunolog-
ical markers, characteristic products, and other appropriate geno-
typic or phenotypic features.
4.3.2.3. Tests of purity. To test the purity of the cell population in a
ﬁnal product, if necessary, set the test parameters, test methods,
and acceptance criteria for evaluating and controlling nontarget
cells, such as undifferentiated cells, cells that exhibit abnormal
growth, transformed cells, and contaminating cells, taking into
consideration such parameters as the origin of the target cells and
tissues, the culture conditions, other parameters of the
manufacturing process, quality control of intermediate products. At
the beginning of the clinical trial, it is acceptable to set provisional
acceptance criteria that are based on measured values obtained for
a small number of test samples.
4.3.2.4. Tests for cell-derived undesirable physiologically active sub-
stances. Specify appropriate tests for determining the permissible
dose limit of any potential undesirable physiologically active sub-
stances that are derived from the target cells if the presence of such
substances in the product is presumed to clearly affect the safety of
the patient. At the beginning of the clinical trial, it is acceptable to
set provisional acceptance criteria that are based on measured
values obtained for a small number of test samples.
4.3.2.5. Tests for process-related impurities. For substances thatmay
be present in the ﬁnal product as, for example, contaminants,
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potentially originate from raw materials, noncellular components,
media ingredients (including feeder cells), chemical reagents, or
any other process-related materials; and that may have deleterious
effects on quality and safety (for example, albumin derived from
fetal calf serum and antibiotics), it is necessary to 1) prove that the
substance is not present in the ﬁnal product by taking into
consideration the results of process evaluations related to the
elimination of the substance or the results of in-process control of
the substance or 2) establish appropriate tests to control permis-
sible levels of the substance in the ﬁnal product. When selecting
substances to be tested and setting their acceptance criteria, their
suitability should be explained and justiﬁed. At the beginning of the
clinical trial, it is acceptable to set provisional acceptance criteria
that are based on measured values obtained for a small number of
test samples.4.3.2.6. Sterility tests and tests for the absence of mycoplasma.
Sterility should be ensured throughout the entire manufacturing
process by evaluating test samples. The sterility (negative results of
tests for common bacteria and fungi) of the ﬁnal product should be
demonstrated before its use in a patient. Appropriate tests con-
ﬁrming the absence of mycoplasma should also be performed. A
validated nucleic-acid ampliﬁcation test can be used. If the results
of sterility and other tests on the ﬁnal product can be obtained only
after the product is administered to the patient, methods for
dealing with the lack of sterility detected after administration
should be established beforehand. In such cases, demonstrate by
testing that the intermediate products are sterile and that sterility
has been strictly maintained in all processes leading to the ﬁnal
product. If a product from the same facility and the same process
has already been used in patients, its sterility must be conﬁrmed by
testing all patients. If complete closure (hermetic seal) of a product
that is a part of a lot has been ensured, tests on representative
samples are sufﬁcient. When each different application needs to be
tested and if the test results can be obtained only after adminis-
tration to the patient, the decision to administer the product will be
based on the most recent data. However, even in such cases, the
ﬁnal product shall be tested.
It is desirable that every effort be made to avoid the use of an-
tibiotics in cell culture systems. However, if antibiotics are used,
adopt measures to ensure that they do not inﬂuence the sterility
tests.4.3.2.7. Endotoxin test. Perform the endotoxin test, taking into
consideration the impact of the contaminant in the samples. The
acceptance criteria do not necessarily depend on the actual
measured values. Set acceptance criteria by taking into consider-
ation the safety ranges in the Japanese Pharmacopoeia and/or any
other relevant compendia that are based on a single dose of the
ﬁnal product. Endotoxin testing can be established as an in-process
control test. However, in such cases, specify the criteria, including
the validation results, and provide the justiﬁcation.4.3.2.8. Virus tests. Use a titer test to detect viruses in the inter-
mediate and ﬁnal products, when using cells that are not banked;
that are from donors not tested during the infection window; and
in which HBV, HCV, HIV, or HTLV can propagate. If materials of a
biological origin are used in the manufacturing process, it may be
necessary to test the ﬁnal product for viruses originating from
those components. However, whenever possible, it is preferable to
determine that there is no contamination by testing at the original
component stage or by process evaluation.4.3.2.9. Speciﬁc biological tests. In some instances, it will be
necessary to consider speciﬁc (quantitative or qualitative) biolog-
ical testing that takes into account the cell type, intended clinical
use, or distinctive characteristics of the cells. At the beginning of the
clinical trial, it is acceptable to set provisional acceptance criteria
that are based on measured values obtained for a small number of
test samples.
4.3.2.10. Potency assay. If a speciﬁc physiologically active substance
that is secreted from cells or tissues contributes to the clinical ef-
ﬁcacy or effect of an allogeneic human somatic stem cell-based
product, establish test parameters and/or acceptance criteria for
the substance in order to demonstrate the intended effect. Set
acceptance criteria for potency or quantitation of a gene expression
product secreted from the cells when a transgene was introduced.
At the beginning of the clinical trial, it is acceptable to set provi-
sional acceptance criteria that are based on measured values ob-
tained for a small number of test samples.
4.3.2.11. Mechanical compatibility tests. For products that require a
certain degree of dynamic strength, set acceptance criteria for
mechanical compatibility and durability that take into account the
site of application. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria that are based on
measured values obtained for a small number of test samples.
5. Chapter III. Stability of allogeneic human somatic stem
cell-based products
Taking into full consideration the storage and distribution pe-
riods and the storage form, test the cell viability, potency, and other
characteristics of allogeneic human somatic stem cell-based prod-
ucts and/or critical intermediate products to establish storage
methods and an expiration date. Provide justiﬁcation for their
suitability. In particular, when product storage and use involves
freezing and thawing, conﬁrm that the freezing and thawing pro-
cesses do not affect the stability or acceptance criteria of the
product. Where necessary and possible, conduct stability studies on
products whose manufacturing period or storage period exceeds
normal periods in order to conﬁrm, to the extent possible, the limits
of stability. This does not apply if a product will be used immedi-
ately after its production.
If an allogeneic human somatic stem cell-based product will be
transported, the relevant transportation vessels and transportation
procedures (such as thermal management) shall be set and their
appropriateness justiﬁed.
6. Chapter IV. Preclinical safety testing of allogeneic human
somatic stem cell-based products
To the extent that they are scientiﬁcally reasonable and tech-
nically possible, relevant animal tests and/or in vitro tests may be
performed in order to address safety concerns associated with an
allogeneic human somatic stem cell-based product. For noncellular
constituents and process-related impurities, safety concerns should
be addressed as much as possible by physicochemical analyses not
by animal testing.
Testing of human specimens is very valuable, whereas testing
the products of human origin in experimental animals does not
always yield meaningful results. Thus, there may be a scientiﬁc
rationale for preparing products of animal origin and testing them
in appropriate experimental animals if such a test system is ex-
pected to generate useful results. In such a case, consider using an
animal model that is suitable for the target disease. (For example,
monkeys may be suitable for studies of neurological diseases, and
T. Hayakawa et al. / Regenerative Therapy 2 (2015) 70e80 79pigs and/or dogs may be suitable for studies of cardiovascular
diseases.) However, because cells with characteristics identical to
those of cells that constitute an allogeneic human somatic stem
cell-based product cannot necessarily be obtained from nonhuman
animal species, even if the preparation procedures are the same,
and because a product of animal cell origin that is manufactured
using identical processes will not necessarily be comparable to a
human cell product, applicants should conduct a feasibility study
before adopting, conducting, and evaluating such tests. When
performing animal experiments using somatic stem cell-based
products obtained from nonhuman animal species, explain why
extrapolation to humans is appropriate. Depending on the case,
consider test systems that employ cells, and clearly explain the
suitability of the test system.
Presented below are items and points to consider and to refer to
when conﬁrming the preclinical safety of a product. These exam-
ples are provided for illustration purposes; they are not intended to
prescribe tests for which there is no rational basis. Taking into
consideration the allogeneic origin of the cells, the characteristics of
the product, the intended clinical use, and other parameters,
conduct necessary and appropriate tests, and evaluate and discuss
the results in a comprehensive manner.
1. For cells expanded beyond the limit set for routine cultivation
(deﬁned by duration of culture, the population doubling level, or
the passage number), demonstrate that alterations other than
those intended have not occurred.
2. It may be necessary to quantify special physiologically active
substances produced by the cells and tissues and to discuss their
effects when they are administered to patients. In some cases,
signiﬁcant amounts of active substances including cytokines
and growth factors would be produced by the cells, potentially
resulting in undesirable effects on the patients.
3. From the standpoint of product safety, examine and discuss the
potential effects of the product on a patient's healthy cells and
tissues and the consequences.
4. Depending on the type of product, investigate and discuss the
possibility of ectopic tissue formation by the cells in the product
and the potential safety consequences thereof when the product
is administered to the patient.
5. Investigate and discuss the possibility of undesirable immuno-
logical reactions caused by the product and/or the expression
product of a transgene and the consequences thereof.
6. Discuss in a comprehensive manner the possibility of tumor
formation, including benign tumors and/or malignant trans-
formation, taking into consideration the type and characteristics
of the product, number of cells, route of administration, mode of
application (e.g., cell sheet or cell suspension), cell engraftment
site, target diseases, and suitability of the test systems, among
other parameters. If necessary, conduct studies on a suitable
animal model. If there is a possibility of tumorigenicity or ma-
lignant transformation, provide justiﬁcation for the use of the
product in question, taking into consideration the anticipated
efﬁcacy. (Note: For tumorigenicity studies, it is very important to
accurately assess tumorigenicity of the ﬁnal product that will be
used in patients. However, tumorigenicity may have to be
evaluated using cells from the intermediate product if, for
various reasons such as an insufﬁcient cell number, the cells in
the ﬁnal product cannot be used. Furthermore, when con-
ducting tumorigenicity tests in animal models, variables such as
cell dispersion, cell adhesion to scaffolding, cell density, and the
administration site may not be the same as those of the ﬁnal
product. The species, strain, and immunological state of the
animal may also affect its sensitivity. The tumorigenicity of the
ﬁnal product should be evaluated in a comprehensive mannertaking these factors into account.) The risks to the patient
arising from tumorigenicity of the ﬁnal product should be
evaluated by weighing the risks of treatment against the ben-
eﬁts of treating the disease.
7. If an exogenous gene is introduced into certain cells during the
manufacturing process, conduct tests in accordance with “Gene
Therapy Pharmaceutical Guidelines”. In particular, if viral vec-
tors are used, perform quantitative tests to determine whether
any replication-competent viruses are present, and provide
justiﬁcation for the test employed. Describe the safety of the
transgene and its products based on their characteristics. For
cells, discuss the possibility of changes in cell growth and of
tumor formation, including benign tumors and malignant
transformation. When using a vector that can get inserted into a
chromosome, consider the necessity of evaluating abnormal
proliferative characteristics and/or tumorigenicity and imple-
menting long-term follow-up.
8. Consider conducting rationally designed general toxicological
tests if the product, including an animal-derived product, is easy
to obtain and if doing so will produce useful information
regarding its clinical application. When conducting general
toxicological tests, refer to “Guidelines for Toxicology Studies on
Pharmaceuticals,” which is an appendix in the document enti-
tled “Guidelines on Toxicology Studies Required for Regulatory
Approval for the Manufacture or Import of Pharmaceuticals”
(Drug Evaluation Notiﬁcation 1:24, issued September 11, 1988,
New Drug Division/Evaluation and Licensing Division, Pharma-
ceutical Affairs Bureau, Japanese Ministry of Health and
Welfare).7. Chapter V. Studies supporting the potency or efﬁcacy of
allogeneic human somatic stem cell-based products
1. A well-designed study on experimental animals and/or cells
should be performed to demonstrate, to a scientiﬁcally
reasonable and technically possible extent, the functional
expression, the sustainability of effects, and/or anticipated
clinical efﬁcacy (proof of concept) of an allogeneic human so-
matic stem cell-based product.
2. For transgenic cells, demonstrate the expression efﬁciency,
sustainability of expression, and biological activity of the
desired products derived from the transgene. Discuss the
rationale of the transgene expression products as active in-
gredients for anticipated clinical efﬁcacy (proof of concept) of
the allogeneic human somatic stem cell-based product in
question.
3. Where appropriate products derived from the processing of
animal somatic stem cells and/or disease model animals are
available, use them to study the potential therapeutic efﬁcacy of
the product.
4. At the beginning of the clinical trial, detailed experimental
studies will not necessarily be required if scientiﬁc literature
and/or other information supports the prediction that the po-
tency or efﬁcacy of the product in question will be markedly
superior to that of a different therapeutic method.8. Chapter VI. Pharmacokinetics of allogeneic human somatic
stem cell-based products
1. Pharmacokinetic studies of the internal behavior of transgene
expression products or cells/tissues that constitute the ﬁnal
products (these studies may include assessment of the absorp-
tion and distribution in experimental animals), should be
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tiﬁcally valid. Thereby, these experiments are expected to esti-
mate the survival of cells/tissues administered to patients and
the duration of their effect and to determine if the intended
efﬁcacy is successfully achieved. (Note: Testing methods may
include histological studies, human Alu sequences ampliﬁcation
by polymerase chain reaction (Alu-PCR), magnetic resonance
imaging (MRI), positron emission tomography (PET), single
photon emission computed tomography (SPECT), and
bioimaging.)
2. For allogeneic human somatic stem cell-based products,
clarify, in animal studies, the rationale for the administration
method. In particular, extrapolate from animal experiments
the systemic distribution of the cells after systemic adminis-
tration and discuss the distribution from the point of view of
clinical usefulness. (Note: Although it is unclear exactly where
the cells adhere with each administration route, local admin-
istration is presumed to be preferable to systemic adminis-
tration. However, if the beneﬁts to patients can be explained, it
is acceptable to use systemic administration. In any case, an
administration method that minimizes the distribution of a
somatic stem cell-based product to organs other than the
target organ would be a rational choice. Even if the cells do
localize to a site other than the intended transplantation site,
this administration method may be used if no effects on pa-
tients result. Arrhythmia caused by osteogenesis of mesen-
chymal stem cells that ectopically locate to the heart is an
example of an adverse effect that can result from ectopic
differentiation.)
3. When the cells or tissues are directly applied or targeted to a
speciﬁc site (e.g., tissue) where they are expected to act, clarify
the localization, and discuss the effect of the localization on the
efﬁcacy and safety of the product.9. Chapter VII. Preliminary analysis of clinical trials
The main purpose of the present guideline is to outline points to
consider for evaluating the quality and safety of allogeneic human
somatic stem cell-based products, at the time of application for
marketing authorization or at the beginning of an investigational
clinical trial. In the latter case, it is necessary to determine, while
taking into consideration the clinical usefulness, whether there are
any quality and/or safety problems that might impede the initiation
of human clinical trials. Thus, quality and nonclinical safety eval-
uation for a decision to initiate the investigational clinical trials of
the product in question should be conducted in reference to the
points outlined below. Any presumed risk factors associated with
product quality and safety should be eliminated, as much as
possible, using up-to-date scientiﬁc and technological methods,
and the scientiﬁc appropriateness should be clearly described. Any
remaining risks should be weighed against the risks associated
with not performing the trials on patients that suffer from diseasesthat are serious and life-threatening, that involve marked func-
tional impairment or a marked decrease in quality of life (QOL)
resulting from the loss of physical function or form, or for which
existing therapies have limitations and do not result in a cure.
Furthermore, it is necessary to entrust the patient with the right to
make a decision after receiving all of the information available,
including all information on identiﬁed/presumed risks and antici-
pated beneﬁts.
1. Target disease.
2. Target subjects and patients who should be excluded as
participants.
3. Details of the therapy to be performed in the subjects, including
the application of allogeneic human somatic stem cell-based
products and drugs used concomitantly. (Note: If it is antici-
pated that drugs will be co-administered in order to maintain,
enhance, and/or induce the function of administered or trans-
planted cells, verify the intended activity of the drugs either
in vitro or in vivo.)
4. The rationale for conducting the clinical trials in light of existing
therapeutic methods.
5. Plan on explaining the clinical trial to the patients, including the
currently known risks and beneﬁts of the product.
Clinical trials should have an appropriate study design and
clearly speciﬁed endpoints. They should be designed in light of the
desired cells/tissues, target disease, and method of application.Disclosures
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